Comparing two treatments for high blood pressure and kidney disease
Part of Heart & circulation clinical trials.
This trial tests if a new treatment combination (finerenone plus a water pill) works better than a standard fixed-dose combination for people with both high blood pressure and chronic kidney disease. It aims to find which option provides more clinical benefit.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have chronic kidney disease with a moderate level of function loss.
- Your kidney function is between 25 and 60 on a specific test (eGFR).
- You have a certain amount of protein in your urine (between 150 and 3500 mg/g).
- Your blood pressure is between 130 and 170 mmHg when sitting.
- You are currently taking up to 80 mg of furosemide (or a similar water pill) and 10 mg of finerenone daily.
- You can follow the study plan and provide written consent.
- You agree to use effective birth control if you are of childbearing age.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether combining two medicines (finerenone and empagliflozin) can help people who are overweight or have obesity and have high blood pressure that is not well controlled. It aims to see if the combination works better than placebo.
This study compares two medications—spironolactone and finerenone—to help manage high potassium levels in people who have heart failure and diabetes-related kidney disease. The goal is to find which medication is safer and more effective for keeping potassium at healthy levels.
This trial tests if finerenone can protect kidneys in people with chronic kidney disease who are not taking common blood pressure medications called ACE inhibitors, ARBs, or renin inhibitors. It may help slow kidney damage.
This study tests whether adding a non-steroidal mineralocorticoid antagonist to your current type 2 diabetes and kidney disease medications (SGLT2i and ACEi/ARB) is cost-effective. It may help preserve kidney function and reduce heart risks.
This trial tests whether combining dapagliflozin (a water-pill-like diabetes drug) with finerenone (a kidney-protective medication) works better than dapagliflozin alone for people with type 2 diabetes and kidney damage. Both drugs help reduce protein in urine and may slow kidney disease progression.
This trial compares two medicines, finerenone and spironolactone, to see which works better and is safer for lowering blood pressure in people with primary aldosteronism. It may help you if you have high blood pressure caused by too much aldosterone.
Hear when a new Hypertension (HTN) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.